A method of sustaining cells is provided. The method can include providing a non-perfluorocarbon cell storage medium, providing a pre-oxygenated liquid perfluorocarbon in contact with the storage medium, and placing the cells in contact with the storage medium but not in contact with the perfluoroca
A method of sustaining cells is provided. The method can include providing a non-perfluorocarbon cell storage medium, providing a pre-oxygenated liquid perfluorocarbon in contact with the storage medium, and placing the cells in contact with the storage medium but not in contact with the perfluorocarbon. Additionally, the method can result in increased corneal cell viability compared to corneal cells placed in a non-perfluorocarbon cell storage medium without being in contact with a pre-oxygenated liquid perfluorocarbon.
대표청구항▼
What is claimed is: 1. A method of sustaining corneal cells, comprising the steps of: providing a non-perfluorocarbon cell storage medium; providing a pre-oxygenated liquid perfluorocarbon underlayer in contact with the storage medium; submersing the corneal cells in the storage medium while not co
What is claimed is: 1. A method of sustaining corneal cells, comprising the steps of: providing a non-perfluorocarbon cell storage medium; providing a pre-oxygenated liquid perfluorocarbon underlayer in contact with the storage medium; submersing the corneal cells in the storage medium while not contacting the perfluorocarbon; and storing the cells at a temperature between-10�� C. to 25�� C. 2. The method according to claim 1, wherein the non-perfluorocarbon storage medium forms a layer on top of the perfluorocarbon. 3. The method according to claim 1, wherein the temperature of the storage medium is maintained at about 4�� C. 4. The method according to claim 1, wherein the perfluorocarbon is selected from the group consisting of perfluorooctylbromide, bis(perfluoro-butyl)ethane, and perfluorooctane. 5. A method for extending the viability of corneal cells that have been removed from a subject, comprising the steps of: providing a non-perfluorocarbon cell storage medium; providing a pre-oxygenated liquid perfluorocarbon in contact with the storage medium; submersing the corneal cells in the storage medium while preventing contact with the perfluorocarbon; and storing the cells at a temperature between-10�� C. to 25�� C. 6. The method according to claim 5, wherein the temperature of the storage medium is maintained at about 4�� C. 7. The method according to claim 1, wherein the perfluorocarbon is about 5% to about 30% of the combined volume of the perfluorocarbon and the storage media. 8. The method according to claim 1, wherein the perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorotripropylamine, perfluoro N-methyl-decahydroisoquinoline, perfluoromethylcyclohexylpiperidine and perfluorodimethylcyclonane. 9. The method according to claim 5, wherein the perfluorocarbon is selected from the group consisting of a perfluorodecalin, perfluorotripropylamine, perfluoro N-methyl-decahydroisoquinoline, perfluoromethylcyclohexylpiperidine and perfluorodimethylcyclonane. 10. The method according to claim 5, wherein the non-perfluorocarbon cell storage medium is corneal storage medium. 11. The method according to claim 10, wherein the corneal storage medium is selected from the group consisting of Optisol, K-Sol, Dexsol, H-Sol, McCarey-Kaufman medium, Corneal Storage Medium, Eagles Media M199, Minimal Essential Media and Phosphate Buffered Saline. 12. The method according to claim 5, wherein the non-perfluorocarbon cell storage medium is Optisol. 13. The method according to claim 1 wherein the cells are sustained in the absence of substantially continuous oxygen bubbling. 14. The method according to claim 5 wherein the cells are maintained in the absence of substantially continuous oxygen bubbling. 15. The method according to claim 1, wherein the cells are completely immersed within the layer of the storage medium. 16. The method according to claim 1, wherein the cells are maintained at about 0�� C. to about 4�� C. 17. The method according to claim 5, wherein the cells are maintained at about 0�� C. to about 4�� C.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (13)
Frossard Philippe M. (Palo Alto CA), Apo AI/CIII genomic polymorphisms predictive of atherosclerosis.
Meinert Hasso (Ulm DEX) Fackler Rudolf (Senden DEX) Mader Juergen (Ulm DEX) Reuter Peter (Ulm-Lehr DEX), Method for preparing perfluorinated heterocyclic compounds, and compounds prepared by this method.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Boyse Edward A. (New York NY) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.